Baker-Groberg SM, Itakura A, Gruber A, McCarty OJ. Role of coagulation in the recruitment of colon adenocarcinoma cells to thrombus under shear. Am J Physiol Cell Physiol 305: C951-C959, 2013. First published July 31, 2013; doi:10.1152/ajpcell.00185.2013.-Colorectal cancer metastases can appear on the peritoneum and in lymph nodes, liver, and lungs, suggesting both hematogenous and lymphatic spreading of the primary tumor. While antithrombotic agents have been shown to reduce both long-term incidence and metastasis, the role of coagulation in facilitating metastasis is ill defined. We investigated the kinetics and molecular mechanisms of metastatic colon adenocarcinoma cell recruitment to thrombi under shear flow, ex vivo. Platelet aggregates were formed by perfusing citrated anticoagulated whole blood over immobilized fibrinogen or fibrillar collagen. Thrombi were formed by perfusing recalcified whole blood over fibrinogen or fibrillar collagen in the presence of coagulation. Cultured colon adenocarcinoma cells (SW620) were perfused either during or following platelet aggregate or thrombus formation. The degree of transient tumor cell interactions (recruitment, rolling, and release) and the number of firmly adhered tumor cells were quantified using fluorescence microscopy. Platelet aggregates and thrombi formed on either fibrinogen-or fibrillar-collagen supported SW620 cell interactions and adhesion under shear. Thrombi or fibrin supported a greater degree of SW620 cell interactions and adhesion compared with platelet aggregates or fibrinogen, respectively, demonstrating that coagulation promoted SW620 cell recruitment under shear. Interestingly, in the absence of anticoagulation, we observed SW620 preferentially binding to thrombus-bound polymorphonuclear leukocytes (PMNs). The addition of purified PMNs to thrombi resulted in a doubling of the number of interacting and bound SW620 cells. Since thrombi often accumulate and activate leukocytes, our findings suggest that leukocytes may play a role in localizing metastases to sites of thrombogenesis. cancer metastasis; inflammation; thrombosis; coagulation; leukocytes THERE IS A CLEAR ASSOCIATION between cancer mortality and metastasis. Cancer metastasis involves the separation of cancer cells from a primary tumor, entrance of tumor cells into the blood or lymphatic circulation, adhesion to or entrapment at a distal site, and proliferation to form a secondary tumor (46, 81) . Successful hematogenous metastasis would require tumor cells to survive in the blood environment and transit of large cells through small vessels that exposes tumor cells to shear forces, all of which could influence tumor cell survival, arrest, and extravasation (22, 78). There has been considerable progress in decoding molecular features of cancer cells; however, the interactions between tumor cells and blood during transit through the vasculature remain ill defined. Local thrombotic blood vessel occlusions are commonly observed on histological evaluation of metastases (31, 33, 63, 64, 76). The aim of this study was to investigate tumor cell recruitment and arrest to thrombi in the presence of coagulation under fluid shear.
cal evaluation of metastases (31, 33, 63, 64, 76) . The aim of this study was to investigate tumor cell recruitment and arrest to thrombi in the presence of coagulation under fluid shear.
The key components of coagulation, platelet activation and fibrinogen, have been implicated in facilitating cancer metastasis (25) . For decades, researchers examining tumor cell arrest in capillaries have observed close relationships between activated platelets and tumor cells (53) . In a pioneering experiment, Gasic et al. (24) demonstrated that thrombocytopenia inhibited metastasis, while platelet activation and infusion restored metastatic potential. More recently, researchers have found that growth factors produced by platelets promote growth of metastatic colon adenocarcinoma cells (9, 23, 34, 47) . In addition to platelet interactions, elevated fibrinogen and soluble fibrin levels have been documented in the blood of many cancer patients (40, 51) , and fibrinogen deficiency significantly reduced spontaneous metastases in mice (12, 66, 67, 68) . Intimate interactions among platelets, fibrinogen, and tumor cells have been observed in the lung vasculature of mice where tumor cells were densely coated with platelets and fibrin clots (11, 18, 37, 48) . Platelet and fibrin adhesion to tumor cells may provide a protective barrier against immune defenses, in particular, defense against the cytotoxicity of natural killer cells (34, 62) . Other studies have suggested tumor cell arrest and formation of a secondary tumor are aided by platelets and fibrin clots providing a mechanism of adhesion and extravasation (7, 18, 22, 34, 57) . However, experimental or clinical evidence for direct inhibition of the progression of metastatic cancer by antithrombotic therapy and consequential improvement in survival is limited, possibly in part because current antithrombotic prophylaxis carries bleeding risks that may counterbalance its benefits.
Elevated levels of circulating leukocytes (leukocytosis) have frequently been observed in cancer patients (5, 58, 73) ; however, how polymorphonuclear leukocytes (PMNs) directly influence cancer progression and metastasis remains unclear. PMNs have been shown to have a cytotoxic effect on tumor cells (19) by maintaining intimate contact with tumor cells and producing reactive oxygen species, membrane-perforating agents, and mediators of cell killing (41) . However, PMNs have also been shown to enhance cancer progression and metastasis (1, 79) . Studies have demonstrated that PMNs can arrest tumor cells in the microvasculature of organs (38, 65, 74) and facilitate their extravasation (74, 82) . Other studies have shown a fluid shear dependence on the kinetics, dynamics, and molecular mechanisms of PMN-tumor cell adhesion and arrest (30, 41, 42, 43) . These data support the notion that PMNs interact with tumor cells while traversing the vasculature and that this interaction may play a significant role in metastasis.
Prior studies investigating tumor cell interactions with blood cells have largely been performed in purified systems (4, 18, 29, 57) . We aimed to extend these studies to characterize tumor cell-blood cell interactions in the presence of coagulation ex vivo under venous shear rates. We found that thrombi supported tumor cell recruitment and adhesion under shear. Importantly, the presence of thrombus-bound PMNs significantly increased the degree of tumor cell adhesion and arrest, suggesting that thrombus-bound PMNs may recruit circulating tumor cells in vivo as well.
MATERIALS AND METHODS
SW620 cell culture. SW620 colon adenocarcinoma cells from lymph node were cultured in DMEM (Invitrogen Life Technologies, Carlsbad, CA), FBS (10% wt/vol; Invitrogen), and penicillinstreptomycin (10% wt/vol; Invitrogen). Cells were detached with TrypLE Select (1ϫ; Invitrogen) for 20 min at 37°C, pelleted at 150 g for 5 min, resuspended to a concentration of 1 ϫ 10 6 cells/ml in serum-free DMEM with Cell Tracker Orange 5-(and-6)-{[(4-chloromethyl)benzoyl]amino}tetramethylrhodamine (CMTMR; 1 M; 30 min at 37°C; Invitrogen), pelleted at 150 g for 5 min to remove excess dye, and resuspended in serum-free DMEM.
Whole blood collection and capillary tube preparation. Venous blood was collected from healthy volunteers in accordance with an Oregon Health & Science University Institutional Review Boardapproved protocol and written informed consent into a one-tenth volume of trisodium citrate to give a final citrate concentration of 12.9 mM. Glass rectangular capillary vitrotubes (0.4 ϫ 4.0 ϫ 50 mm; VitroCom; Mountain Lakes, NJ) were coated with either fibrillar equine type I collagen (100 g/ml; Chronolog, Havertown, PA) or fibrinogen (FG; 50 g/ml; Kordia Laboratory Supplies, Leiden, The Netherlands) for 1 h at 25°C, followed by washing with PBS. Protein-coated slides were then blocked with fatty acid free BSA (5 mg/ml; 1 h at 25°C; Sigma-Aldrich), followed by final washing with PBS. Coated vitrotubes were assembled onto microscope slides and mounted onto the stage of an inverted microscope (Zeiss Axiovert 200M; Carl Zeiss MicroImaging).
PMN purification. Human venous blood was collected from healthy volunteers into citrate phosphate dextrose (7:1 vol/vol), and PMNs were purified as described previously (39) . Purified PMNs were incubated with Cell Tracker Blue 7-amino-4-shloromethylcoumarin (CMAC; 1 M; 30 min at 37°C; Invitrogen) at a concentration of 1 ϫ 10 6 PMNs/ml, pelleted at 400 g for 10 min, and resuspended in PMN leukocyte buffer. SW620 cell perfusion experiments. A pulse-free syringe pump perfused trisodium citrated anticoagulated blood through fibrillar collagen-or fibrinogen-coated vitrotubes for 5 min at a shear rate of 265 s Ϫ1 to form platelet aggregates. To form thrombi, citrated blood was mixed with calcium flow buffer (75 mM CaCl2 and 37.5 mM MgCl2) at one-tenth of the blood flow rate using a separate syringe pump immediately before perfusion to allow for activation of the coagulation cascade and limited thrombin generation during flow through the tube. Vitrotubes containing either platelet aggregates or thrombi were then washed for 5 min with modified HEPES/Tyrode buffer (136 mM NaCl, 2.7 mM KCl, 10 mM HEPES, 2 mM MgCl 2, 2 mM CaCl2, 5.6 mM glucose, and 0.1% BSA pH 7.45) at the same shear rate to remove unbound blood components. In selected experiments, calcium flow buffer supplemented with 50 pM tissue factor, as previously described (8) , was mixed with purified pooled plasma from three separate donors before perfusion through fibrinogen-coated vitrotubes. Subsequently SW620 cells at 1 ϫ 10 6 cells/ml were perfused at 25, 35, 75, 100, or 150 s Ϫ1 shear rate for 1 min over a surface of BSA, fibrin(ogen), or the formed platelet aggregates or thrombi. The number of transiently interacting cells (recruitment, rolling, and release) or firmly adhered cells was quantified through fluorescent video capture (ϫ20 magnification; SlideBook 5.5 software; Intelligent Imaging Innovations, Denver, CO).
In some experiments, citrated anticoagulated blood was incubated with fluorescent CMTMR SW620 cells at 1 ϫ 10 6 cells/ml for 5 min, followed by perfusion over fibrillar collagen-or fibrinogen-coated vitrotubes for 5 min at a shear rate of 25, 35, 75, 100, or 150 s Ϫ1 to form platelet aggregates. The rates of transiently interacting cells or firmly adhered cells were quantified using fluorescent video capture. In selected experiments, citrated anticoagulated blood was treated with a coagulation factor Xa inhibitor (rivaroxaban; 10 M; Bayer Healthcare, Leverkusen, Germany), a thrombin inhibitor (hirudin; 20 g/ml; CIBA-Geigy Pharmaceuticals, Horsham, West Sussex, United Kingdom), or a coagulation factor XIIa inhibitor [corn trypsin inhibitor (CTI); 20 g/ml; Enzyme Research Laboratories, South Bend, IN] for 10 min before recalcification.
PMN-SW620 cell flow perfusion. Platelet aggregates or thrombi were formed at 265 s Ϫ1 over a fibrinogen-coated surface, followed by the perfusion of purified fluorescent CMAC PMNs (1 ϫ 10 6 PMNs/ ml) for 1 min at the same shear rate. SW620 cells were then perfused over the formed aggregates or thrombi with PMNs at 25, 35, 75, 100, or 150 s Ϫ1 for 1 min. Cell interaction rates were quantified through fluorescent video capture.
Statistical analysis. Data are represented as means Ϯ SE. Each experimental condition was repeated at least three times. Statistical analysis was performed using paired Student's t-test. Significance for all statistical tests required P value Յ0.05.
RESULTS

SW620 cells interact with platelet aggregates and thrombi in a shear-dependent manner.
Initial experiments were designed to analyze the rate of tumor cell interactions (recruitment, rolling, and release or firm adhesion) with platelets and thrombi under flow. Tumor cells were perfused in a parallel plate flow chamber either during or following platelet aggregate of thrombus formation. Platelet aggregates were formed by perfusing citrated whole blood over surfaces of fibrinogen or fibrillar collagen. Thrombi were formed by coperfusing calcium flow buffer with citrated anticoagulated whole blood over surfaces of fibrinogen or fibrillar collagen. Recalcification with calcium flow buffer allows the coagulation cascade to be triggered to generate thrombin and fibrin formation (termed thrombi). Fluorescent CMTMR SW620 cells were perfused either during or following platelet aggregate or thrombus formation at shear rates ranging from 25 to 150 s Ϫ1 (Fig. 1,  A-D) . Transiently interacting and firmly adherent cells were defined as SW620 cells that were recruited and either released in Ͻ60 s or remained bound for Ͼ60 s, respectively. Transiently interacting and firmly adherent SW620 cells on platelet aggregates or thrombi were highly dependent on shear rate (Fig. 2) . A maximal rate of SW620 cell recruitment and adhesion to platelet aggregates or thrombi was observed at 25 s Ϫ1 , while no interactions were observed Ͼ100 s Ϫ1 . Total interacting cells were calculated by adding the rates of transiently interacting and firmly adherent cells. As shown in Fig. 3, A and B, on a fibrinogen surface, the rate of total interacting SW620 cells with thrombi was nearly double compared with the rate of total interacting SW620 cells with platelet aggregates at 25 s Ϫ1 , regardless of whether SW620 cells were perfused with the blood or following aggregate or thrombus formation. An equivalent rate of total interacting SW620 cells with platelet aggregates or thrombi formed on collagen was observed at 25 s Ϫ1 ; however, thrombi formed on collagen supported a significantly greater degree of SW620 cell interactions at both 35 and 75 s Ϫ1 compared with platelet aggregates when SW620 cells were perfused following aggregate or thrombus formation (Fig. 3, A and B) .
To compare the extent of SW620 cell interactions with platelet aggregates and thrombi under shear, we calculated the total rate of interacting cells by cumulating the transiently interacting and firmly adherent across all shear rates. When SW620 cells were perfused over platelet aggregates or thrombi, the presence of coagulation significantly increased the total level of cell interactions for both fibrinogen and collagen surfaces (Fig. 3C ). Under these conditions, platelet aggregates or thrombi formed on collagen surfaces supported increased levels of total interactions compared with fibrinogen (Fig. 3C) .
Previous studies have demonstrated that the conversion of fibrinogen to fibrin enhanced tumor cell recruitment under flow in a purified system (3). We next designed experiments to compare the recruitment of SW620 cells to a surface of fibrin formed in plasma or a surface of fibrinogen. Our data show that perfusion of SW620 cells over fibrinogen surfaces resulted in a mean interaction rate of 65 cells/mm 2 , while recruitment rates of SW620 cells over the fibrin surface resulted in a significantly greater mean adhesion rate of 228 cells/mm 2 (Fig. 4) . In contrast, SW620 cells failed to bind to a surface of BSA (Fig. 4) .
Role of coagulation factors in SW620 cell recruitment and adhesion to thrombi under shear. Subsequent experiments focused on defining the role of the contact activation pathway of blood coagulation in SW620 cell recruitment and adhesion to thrombi under shear. When recalcified blood was pretreated with a thrombin inhibitor (hirudin), a factor Xa (FXa) inhibitor (rivaroxaban), or a factor XIIa (FXIIa) inhibitor (CTI) before perfusion over fibrinogen or collagen, the rate of SW620 recruitment and adhesion was significantly reduced (Fig. 5) . Moreover, hirudin, rivaroxaban, or CTI reduced the total rate of interacting SW620 cells with thrombi to the levels observed on platelet aggregates in the absence of coagulation (Fig. 6) . Taken together, our data demonstrate a critical role for coagulation activation in potentiating tumor cell recruitment to thrombi under shear.
PMNs increase the rate of SW620 cell interactions to platelet aggregates and thrombi under shear. Our next set of experiments was designed to determine whether thrombusbound PMNs played a role in tumor cell recruitment and adhesion under shear. SW620 cells tethered to and adhered downstream of thrombus-bound PMNs (Fig. 7, A and B ; Supplemental Movie S1; Supplemental Material for this article is available online at the Am J Physiol Cell Physiol website). The presence of thrombus-bound PMNs significantly increased the rate of SW620 transient interactions and firm adhesion (Fig. 7, B and C) . The total interaction rates of SW620 cells with thrombi increased from 169 Ϯ 16 to 303 Ϯ 31 cells·mm Ϫ2 ·min Ϫ1 at 25 s Ϫ1 in the presence of thrombusbound PMNs (Fig. 7D) .
DISCUSSION
The main findings of this study are the following: 1) colon adenocarcinoma cells bind thrombi in a shear-dependent man- ner; 2) tumor cells interact with thrombi in a thrombin-and FXa-dependent manner; and 3) PMNs promote SW620 cell recruitment and adhesion to thrombi under shear.
SW620 cells interact with thrombi in a shear-dependent manner. Previous studies using purified systems have demonstrated the shear rate dependence of tumor cell-platelet interactions. In the present work, we found that tumor cell-thrombus interactions in the presence of coagulation decreased as shear rates increased from 25 to 75 s Ϫ1 . These shear rates coincide with the blood shear rates found in capillary beds (ϳ32 to 43 s Ϫ1 reported for the human and mouse capillary bed, respectively; Refs. 15, 55) and postcapillary venules (ϳ35 to 560 s Ϫ1 ; Refs. 34, 49) . Tumor cell arrest has been observed in vivo in both capillary beds (13, 21, 60) and postcapillary venules (45, 52) . Tumor cell arrest in capillaries has been hypothesized to be a passive process, wherein circulating tumor cells, which range in size from 9 to 12 m in diameter in patient samples (70, 71) , are physically trapped in small capillaries, which range in size from 5-10 m in diameter and number in the billions in the human body (59) . The SW620 cells used in this study ranged in size from 8 to 12 m (Figs.  1 and 2, A and B) , which coincides with the sizes of circulating tumor cells trapped in vivo. For circulating tumor cells that make it through the metarterioles and arteriovenous bypasses that regulate tissue perfusion, they next enter venules and veins. This vessel expansion through the postcapillary venules creates a reduction in blood velocity and an increase in pressure, which can result in small turbulent eddies at the edges of the expanding vessel (69). Areas of turbulence or stagnant flow in the postcapillary venules may provide favorable conditions for tumor cell arrest in the vasculature during metastasis through both passive and active mechanisms (75) .
We found that SW620 cell recruitment to thrombi formed on fibrillar collagen was significantly greater than the extent of recruitment to thrombi formed on fibrinogen. Fibrillar collagen is a potent platelet agonist and supports platelet recruitment, activation, and aggregate formation under high shear (14) . In parallel, collagen also activates coagulation factor XII, initiating thrombin generation and fibrin formation (80) . The discrete fibrillar nature of collagen results in three-dimensional thrombus formation being localized along the collagen fibers in the direction of shear flow (6) . In contrast, only a single layer of platelets forms on fibrinogen under shear, resulting in a "two- Fig. 6 . Role of coagulation factor X and thrombin in SW620 cell recruitment to thrombus under shear. Citrated anticoagulated blood was incubated with a thrombin inhibitor (hirudin; 20 g/ml), a coagulation factor Xa inhibitor (rivaroxaban; 10 M), or a coagulation factor XIIa inhibitor [corn trypsin inhibitor (CTI); 20 g/ml]. Blood was perfused over a fibrinogen (A)-or fibrillar collagen (B)-coated surface (ϪCalcium). In selected experiments, whole blood was coperfused with calcium flow buffer (ϩCalcium). Fluorescent SW620 cells were then perfused and the total rates of interacting SW620 cells across all shear rates were calculated for each treatment. Data are represented as means Ϯ SE of 3 individual experiments. *P Ͻ 0.05 for coagulation inhibitor treatment compared with vehicle. Fig. 5 . Coagulation inhibitors decrease SW620 adenocarcinoma cell transient interactions and adhesion rate to thrombi under shear. Sodium citrated anticoagulated human whole blood was incubated with a thrombin inhibitor (hirudin; 20 g/ml), a coagulation factor Xa inhibitor (rivaroxaban; 10 M), or a coagulation factor XIIa inhibitor (corn trypsin inhibitor, CTI; 20 g/ml) for 10 min at 25°C. Blood was then perfused over a fibrinogen-or fibrillar collagen-coated surface at 265 s Ϫ1 (ϪCalcium). In selected experiments, whole blood was co-perfused with calcium flow buffer (ϩCalcium). Fluorescent SW620 cells were perfused over formed platelet aggregates or thrombi at 25, 35, 75, or 100 s dimensional" platelet-rich thrombus forming in the presence of coagulation. The results indicate that thrombus formation on collagen creates a structure that is both physically and biochemically more active for tumor cell recruitment, ex vivo.
Further, our results demonstrating that fibrin formed in plasma enhanced SW620 cells recruitment compared with fibrinogen support the notion that the conversion of fibrinogen to fibrin potentiates this receptor-ligand interaction (3, 4, 56) . 
Role of thrombin and FXa in SW620 cell-thrombi interactions.
Coagulation is triggered by the exposure of blood to extracellular matrix proteins and localized to the surface of activated platelets. The intrinsic and extrinsic pathways of coagulation converge to activate FX to FXa, which in turn activates prothrombin to generate thrombin, which in turn activates platelets and coagulation factors, cleaves fibrinogen to fibrin resulting in the formation of a thrombus or a hemostatic plug. Coagulation proteases, such as FXa and thrombin, have been shown to directly regulate cancer cell growth and motility (35, 72, 83) . Moreover, circumstantial evidence suggests that FXa and thrombin may support cancer metastasis (20, 61, 77) via direct or indirect mechanisms. For instance, studies have shown that targeting FXa with low-molecular weight heparin increases cancer survival (2, 10, 36, 44) . We show that inhibition of either FXa or thrombin significantly reduced the degree of SW620 cell recruitment to thrombi under shear, highlighting a role for these coagulation factors in promoting tumor cell-thrombus interactions. If thrombi that recruited tumor cells provide an environment that is favorable for survival and proliferation of circulating cancer cells, inhibition of thrombin generation could indeed provide anti-metastatic effects and survival benefit in patients.
PMNs promote SW620 cell adhesion and arrest to thrombi under shear. Numerous studies have reported a link between inflammation and cancer metastasis (16, 27, 50, 54) . It has been previously demonstrated that PMNs are capable of binding tumor cells in a shear-dependent manner in purified systems (42) . It is also known that PMNs are often associated with and incorporated into developing thrombi (28) . Here we show that thrombus-bound PMNs promoted tumor cell recruitment and adhesion from blood under shear, ex vivo. In the vasculature, PMNs are recruited to the endothelium of inflamed postcapillary venules in a series of steps involving PMN capture, activation and rolling, firm adhesion, and migration. Studies also show that PMNs are recruited to experimental thrombi at sites of endothelial injury. Predominantly observed in the venous circulation, intravascular leukocyte migration within a thrombus has been shown to guide leukocytes toward a site of vascular injury (26) . Our findings suggest that thrombus-bound PMNs may augment the recruitment of circulating tumor cells in vivo. This, in theory, could contribute to the seeding and proliferation of circulating cancer cells and accelerate the progression of metastatic cancer. Thrombus-associated leukocyte accumulation and tumor cell recruitment thus could provide a rationale for antithrombotic prophylaxis of cancer patients. However, it remains to be determined if the leukocyterecruited cancer cell is in a microenvironment that favors proliferation.
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